October was a busy month for the pulmonary hypertension community. The Alliance for Pulmonary Hypertension added five new PEP Talks and, together with the European Pulmonary Fibrosis Federation (EU-PFF), held a webinar on pulmonary hypertension associated with interstitial lung disease.
On the treatment front Gossamer Bio has submitted a New Drug Application (NDA) for seralutinib to the United States Food and Drug Administration, the first generic version of riociguat is now available in the US, new data on a once-daily inhaled form of treprostinil look encouraging, and several other drugs are moving through clinical trials. Transplantation also featured strongly this month, from the European Day for Organ Donation and Transplantation to a French study of lung transplant outcomes and United Therapeutics’ investment in producing organs for transplant.
Finally, research continues to broaden our understanding of the disease. This month’s studies looked at the first experience with sotatercept in children, as well as the first real-world experience with it in the Middle East. Other studies covered personalised treatment based on patients’ molecular profiles, and a simple blood test index, PALBI, based on platelet, albumin and bilirubin levels, to predict hospitalisation and death. A review also looked at how the typical patient is changing as the population ages and obesity becomes more common. Together, these articles give a snapshot of a field that is moving forward on several fronts at once.
Alliance for Pulmonary Hypertension announcements
- Five new videos from our 2026 PEP Talks series, October 2026
- Joint webinar of the Alliance for Pulmonary Hypertension and the European Pulmonary Fibrosis Federation on pulmonary hypertension associated with interstitial lung disease, October 21, 2026
Industry news
- Gossamer Bio submits New Drug Application to the United States Food and Drug Administration for seralutinib in pulmonary arterial hypertension, Business Wire, September 23, 2026
- Zydus Lifesciences and MSN Laboratories partner to launch first generic of Adempas (riociguat) in the United States, PR Newswire, October 5, 2026
- Update on the global Phase 2b EPIMODE trial evaluating Cereno Scientific’s drug candidate CS1 in pulmonary arterial hypertension, Modular Finance, October 8, 2026
- Alaunos Therapeutics has bought Velaris Therapeutics, which is developing four biological drugs for pulmonary arterial hypertension and related heart and lung diseases, FirstWord Pharma, October 13, 2026
- Extension studies of Insmed’s treprostinil palmitil inhalation powder (TPIP) show promise in pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, American Journal of Managed Care, October 20, 2026
- Update on LAM-001, an investigational formulation of inhaled rapamycin being developed by IRulya Therapeutics for multiple pulmonary diseases, including pulmonary hypertension associated with interstitial lung disease and bronchiolitis obliterans syndrome after lung transplant, Globenewswire, October 9, 2026
- United Therapeutics opens xeno organ production sites in Houston and Stewartville, Simply Wall Street, October 24, 2026
Research
- Sotatercept in Paediatric Pulmonary Hypertension: Experience from the Pediatric Pulmonary Hypertension Network, CHEST Journal, October 5, 2026
- First Report of Real World Utilization of an Activin Signaling Inhibitor in Patients With Severe Pulmonary Arterial Hypertension in the Middle East, Pulmonary Circulation, October 22, 2026
- The Evolving Role of Inhaled Therapies in pulmonary arterial hypertension and pulmonary hypertension linked to interstitial lung disease, European Medical Journal, October 20, 2026
- Researchers at Brown University find that molecular profiles may help create more effective individualized treatment for pulmonary arterial hypertension, The Brown Daily Herald, October 15, 2026
- Impaired bone morphogenetic protein receptor type 2 signalling across pulmonary hypertension subgroups: a multicentre study, European Respiratory Journal Open Research, September 28, 2026
- Treatment Strategies for Achieving and Maintaining Low-Risk Status in Pulmonary Arterial Hypertension: A Systematic Review, Cureus, October 18, 2026
- Contemporary Economic, Hospitalization, and Mortality Burden Among Pulmonary Arterial Hypertension Patients: A Real-World United States Claims Data Analysis, Pulmonary Circulation, October 6, 2026
- Global data on pulmonary arterial hypertension in people aged 60 and over reveals diverging trajectories in rich and poor nations, Pulmonary Hypertension News, October 12, 2026
- Pulmonary arterial hypertension in the era of obesity: navigating phenotypes of pulmonary hypertension, Expert Review of Respiratory Medicine, October 22, 2026
- Estimating mean pulmonary arterial pressure in the machine learning era, European Respiratory Journal, October 9, 2026
- Platelet–Albumin–Bilirubin Index (PALBI) for Predicting Hospitalization and Mortality in Pulmonary Hypertension, Circulation Journal,
Transplantation
- Evolving profile and outcomes of patients with pulmonary arterial hypertension undergoing lung transplantation in France, Journal of Heart and Lung Transplantation Open, 3 September 2026